메뉴 건너뛰기




Volumn 36, Issue 6, 2008, Pages 1418-1425

Impression of clinical worsening fails to predict interferon-β neutralizing antibody status

Author keywords

Indications for testing; Interferon ; Multiple sclerosis; Neutralizing antibodies; Treatment

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; REBIF 22; REBIF 44; UNCLASSIFIED DRUG; AUTOANTIBODY; BETA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEINS;

EID: 59649088072     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600631     Document Type: Article
Times cited : (5)

References (20)
  • 1
    • 3242877381 scopus 로고    scopus 로고
    • Immunogenicity of interferon beta: Differences among products
    • Bertolotto A, Deisenhammer F, Gallo P, et al: Immunogenicity of interferon beta: differences among products. J Neurol 2004; 251(suppl 2): II15-II24.
    • (2004) J Neurol , vol.251 , Issue.SUPPL. 2
    • Bertolotto, A.1    Deisenhammer, F.2    Gallo, P.3
  • 2
    • 0037465461 scopus 로고    scopus 로고
    • Persistent neutralizing antibodies abolish the interferon β bioavailabity in MS patients
    • Bertolotto A, Gilli F, Sala A, et al: Persistent neutralizing antibodies abolish the interferon β bioavailabity in MS patients. Neurology 2003; 60: 634-639.
    • (2003) Neurology , vol.60 , pp. 634-639
    • Bertolotto, A.1    Gilli, F.2    Sala, A.3
  • 3
    • 0005489101 scopus 로고    scopus 로고
    • The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894
    • The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
  • 4
    • 0035954361 scopus 로고    scopus 로고
    • PRISMS-4: Long-term efficacy of interfero-β-1a in relapsing MS
    • PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group
    • PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group: PRISMS-4: long-term efficacy of interfero-β-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
    • (2001) Neurology , vol.56 , pp. 1628-1636
  • 5
    • 22044450811 scopus 로고    scopus 로고
    • Neutralizing antibodies and efficacy of interferon β-1a: A 4-year controlled study
    • Kappos L, Clanet M, Sandberg-Wollheim M, et al: Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
    • (2005) Neurology , vol.65 , pp. 40-47
    • Kappos, L.1    Clanet, M.2    Sandberg-Wollheim, M.3
  • 6
    • 22044436956 scopus 로고    scopus 로고
    • Interferon β-1a in MS: Results following development of neutralizing antibodies in PRISMS
    • Francis GS, Rice GP, Alsop JC: Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
    • (2005) Neurology , vol.65 , pp. 48-55
    • Francis, G.S.1    Rice, G.P.2    Alsop, J.C.3
  • 7
    • 10744225329 scopus 로고    scopus 로고
    • Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing - remitting multiple sclerosis
    • Sorensen PS, Ross C, Clemmesen KM, et al: Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing - remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
    • (2003) Lancet , vol.362 , pp. 1184-1191
    • Sorensen, P.S.1    Ross, C.2    Clemmesen, K.M.3
  • 8
    • 27744509228 scopus 로고    scopus 로고
    • Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis
    • Sorensen PS, Deisenhammer F, Duda P, et al: Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
    • (2005) Eur J Neurol , vol.12 , pp. 817-827
    • Sorensen, P.S.1    Deisenhammer, F.2    Duda, P.3
  • 9
    • 27844448644 scopus 로고    scopus 로고
    • Can the course of multiple sclerosis be modified?
    • Coles A: Can the course of multiple sclerosis be modified? Pract Neurol 2005; 5: 278-287.
    • (2005) Pract Neurol , vol.5 , pp. 278-287
    • Coles, A.1
  • 10
    • 34147167957 scopus 로고    scopus 로고
    • Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis
    • Goodin DS, Hurwitz BJ, Noronha A: Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007; 35: 173-187.
    • (2007) J Int Med Res , vol.35 , pp. 173-187
    • Goodin, D.S.1    Hurwitz, B.J.2    Noronha, A.3
  • 11
    • 39149099154 scopus 로고    scopus 로고
    • Neutralizing antibodies to interferon 1b are not associated with disease worsening in multiple sclerosis
    • Farrel R, Bendtzen K, Berlotto A, et al: Neutralizing antibodies to interferon 1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2008; 36: 204-208.
    • (2008) J Int Med Res , vol.36 , pp. 204-208
    • Farrel, R.1    Bendtzen, K.2    Berlotto, A.3
  • 12
    • 34247092348 scopus 로고    scopus 로고
    • Interferon beta preparations for treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
    • Sominada A, Rot U, Suoniemi M, et al: Interferon beta preparations for treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007; 13: 208-214.
    • (2007) Mult Scler , vol.13 , pp. 208-214
    • Sominada, A.1    Rot, U.2    Suoniemi, M.3
  • 13
    • 0022555790 scopus 로고
    • Quantitation of neutralization of interferon by antibody
    • Kawade Y: Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558-573.
    • (1986) Methods Enzymol , vol.119 , pp. 558-573
    • Kawade, Y.1
  • 14
    • 37749040878 scopus 로고    scopus 로고
    • In vivo bioactivity of interferon beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
    • Sominada A, Hillert J, Fogdell-Hahn A: In vivo bioactivity of interferon beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 57-62.
    • (2008) J Neurol Neurosurg Psychiatry , vol.79 , pp. 57-62
    • Sominada, A.1    Hillert, J.2    Fogdell-Hahn, A.3
  • 15
    • 33750990488 scopus 로고    scopus 로고
    • Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS
    • Sorensen PS, Tscherning T, Mathiesen HK, et al: Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 647: 1681-1683.
    • (2006) Neurology , vol.647 , pp. 1681-1683
    • Sorensen, P.S.1    Tscherning, T.2    Mathiesen, H.K.3
  • 16
    • 0035849496 scopus 로고    scopus 로고
    • Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results
    • Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group
    • Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504.
    • (2001) Neurology , vol.56 , pp. 1496-1504
  • 17
    • 20144382021 scopus 로고    scopus 로고
    • Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis
    • Rio J, Porcel J, Tellez N, et al: Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis. Mult scler 2005; 11: 306-309.
    • (2005) Mult scler , vol.11 , pp. 306-309
    • Rio, J.1    Porcel, J.2    Tellez, N.3
  • 18
    • 0037181634 scopus 로고    scopus 로고
    • Every-other-day interferon beta-1b versus once-weekly interferon-beta 1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)
    • Durelli L, Verdun E, Barbero P, et al: Every-other-day interferon beta-1b versus once-weekly interferon-beta 1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
    • (2002) Lancet , vol.359 , pp. 1453-1460
    • Durelli, L.1    Verdun, E.2    Barbero, P.3
  • 19
    • 0037180479 scopus 로고    scopus 로고
    • Randomized, comparative study of interferon 1a regimens in MS. The EVIDENCE Trial
    • Panitch H, Goodin DS, Francis G, et al: Randomized, comparative study of interferon 1a regimens in MS. The EVIDENCE Trial. Neurology 2002; 59: 1496-1506.
    • (2002) Neurology , vol.59 , pp. 1496-1506
    • Panitch, H.1    Goodin, D.S.2    Francis, G.3
  • 20
    • 0034702233 scopus 로고    scopus 로고
    • A comparison of observational studies and randomized, controlled trials
    • Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 200; 342: 1878-1886.
    • N Engl J Med , vol.200 , Issue.342 , pp. 1878-1886
    • Benson, K.1    Hartz, A.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.